AstraZeneca, the British drugmaker, today said that clinical trials for the vaccine have resumed in Japan.
The firm is still in talks with regulators over data needed to restart trials in the US, which is one of the countries where the trials had been put on pause.
Last month, regulators in the UK, Brazil, South Africa, India said that trials were safe to continue.
The company said: “AstraZeneca continues to work with the Food and Drug Administration (FDA) to facilitate review of the information needed to make a decision regarding resumption of the US trial. The safety of trial participants is of paramount importance and we are committed to upholding the highest standards of conduct in clinical trials.”